QOL Up With Pembrolizumab Versus Ipilimumab, HDI in Resected Melanoma
Quality of life favored the pembrolizumab arm versus standard - of - care arm receiving ipilimumab, high - dose interferon α 2b (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 28, 2022 Category: Cancer & Oncology Tags: Dermatology, Oncology, Pharmacy, Surgery, Journal, Source Type: news

QOL Up With Pembrolizumab Versus Ipilimumab, HDI in Resected Melanoma
MONDAY, Nov. 28, 2022 -- For patients with high-risk resected melanoma, adjuvant pembrolizumab improves quality of life (QOL) compared with standard of care with ipilimumab or high-dose interferonα 2b (HDI), according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 28, 2022 Category: Pharmaceuticals Source Type: news

Immunotherapy Doublet Shows Promise for Nonsurgical Control of Small Kidney Cancers
(MedPage Today) -- AUSTIN, Texas -- Unresectable nonmetastatic kidney cancers regressed substantially, but not completely, in response to treatment with nivolumab (Opdivo) and ipilimumab (Yervoy), a small prospective study showed. Six of eight... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 7, 2022 Category: Hematology Source Type: news

A Cost-Effective De-escalation Strategy in Advanced Melanoma A Cost-Effective De-escalation Strategy in Advanced Melanoma
Response-adapted de-escalation of ipilimumab in patients with advanced melanoma has the potential to lower healthcare costs.Medscape Medical News (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - October 31, 2022 Category: Radiology Tags: Hematology-Oncology News Source Type: news

Latest Mesothelioma T-Cell Clinical Trial Moves to Phase II
The most recent T-cell therapy aimed at mesothelioma cancer has advanced to phase II of the clinical trial process, with researchers exploring its effectiveness when combined with an already approved immunotherapy duet. Investigators are studying the synergistic effect of gavocabtagene autoleucel (gavo-cel) when used with the combination of Opdivo and Yervoy, which was approved by the U.S. Food and Drug Administration in 2020 to treat mesothelioma. Its earlier phase I results, when used alone, were impressive – 93% of patients experienced tumor regression – raising hopes for a much-needed advancement in mesotheli...
Source: Asbestos and Mesothelioma News - October 17, 2022 Category: Environmental Health Authors: Lynette Zilio Source Type: news

Study: Cancer Enzyme Slows Growth of Pleural Mesothelioma
Patients with pleural mesothelioma may extend their survival by an estimated 30% when the latest anti-cancer enzyme is added to standard chemotherapy, according to a recently completed study. AGI-PEG 20 showed unprecedented effectiveness when treating patients with sarcomatoid mesothelioma and biphasic mesothelioma – the most treatment-resistant subtypes – in an international, multicenter, phase II/III clinical trial known as ATOMIC Meso. The enzyme works by limiting an amino acid known as arginine that often fuels tumor cells. It depletes its effectiveness in promoting tumor growth, leading to longer survival. ...
Source: Asbestos and Mesothelioma News - October 13, 2022 Category: Environmental Health Authors: Fran Mannino Source Type: news

Treatment Sequence Studied for Advanced BRAF - Mutant Melanoma
Two - year overall survival higher for those initiating treatment with combo nivolumab/ipilimumab versus dual BRAF/MEK inhibition (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 6, 2022 Category: Cancer & Oncology Tags: Dermatology, Oncology, Pharmacy, Journal, Source Type: news

Treatment Sequence Studied for Advanced BRAF-Mutant Melanoma
THURSDAY, Oct. 6, 2022 -- For patients with treatment-naive BRAFv600 mutant metastatic melanoma, treatment first with combination nivolumab/ipilimumab yields better overall survival than dual BRAF/MEK inhibition with dabrafenib/trametinib, according... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 6, 2022 Category: Pharmaceuticals Source Type: news

Triplet Therapy Ups Progression - Free Survival in Advanced Kidney Cancer
PFS improved with cabozantinib + nivolumab + ipilimumab for patients with previously untreated advanced renal cell carcinoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 27, 2022 Category: Cancer & Oncology Tags: Nephrology, Oncology, Pharmacy, Conference News, Source Type: news

Triplet Therapy Ups Progression-Free Survival in Advanced Kidney Cancer
MONDAY, Sept. 26, 2022 -- Triplet therapy of cabozantinib + nivolumab + ipilimumab significantly improves progression-free survival (PFS) compared with placebo + nivolumab + ipilimumab for patients with previously untreated advanced renal cell... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 27, 2022 Category: Pharmaceuticals Source Type: news

Adjuvant Nivolumab + Ipilimumab Lacks Efficacy for Localized RCC
WEDNESDAY, Sept. 14, 2022 -- Disease-free survival (DFS) does not differ with adjuvant nivolumab plus ipilimumab (NIVO+IPI) compared with placebo in patients with localized renal cell carcinoma (RCC) at high risk for postnephrectomy relapse,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 14, 2022 Category: Pharmaceuticals Source Type: news

' Unprecedented' Responses to Neoadjuvant Tx in dMMR Colon Cancer'Unprecedented' Responses to Neoadjuvant Tx in dMMR Colon Cancer
An ' innovative ' study of short-course nivolumab plus ipilimumab prior to resection of MMR-deficient colon cancer has achieved ' unprecedented ' pathologic responses, with no recurrences.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 11, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Adjuvant Nivo+Ipi Fails in Kidney Cancer, in Contrast to Pembro Adjuvant Nivo+Ipi Fails in Kidney Cancer, in Contrast to Pembro
Six months of adjuvant nivolumab plus ipilimumab after nephrectomy for renal cell carcinoma offers no disease-free survival benefit, reveals trial that highlights treatment duration and tolerability.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 11, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Novel Cell Therapy Beats Immunotherapy in Melanoma Novel Cell Therapy Beats Immunotherapy in Melanoma
A novel cell therapy made from tumor infiltrating lymphocytes (TILs) was superior to ipilimumab, and may be a new treatment option for advanced stage melanoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 10, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Mesothelioma Clinical Trial Studies Keytruda, Lenvatinib Combination
The objective response rate of the Keytruda/lenvatinib combination was an impressive 58%. In 2020, the U.S. Food and Drug Administration approved the use of Keytruda for certain metastatic tumors, including certain cases of mesothelioma, but the search for an effective combination continues. Lenvatinib has shown it can block tumor growth by targeting specific proteins Keytruda can’t reach. It has been effective with only select cancers and is known as precision medicine. The drug, which is already FDA approved, has been used successfully with Keytruda for the treatment of endometrial cancer. Lenvatinib is prescr...
Source: Asbestos and Mesothelioma News - August 17, 2022 Category: Environmental Health Authors: Fran Mannino Tags: Clinical Trials/Research/Emerging Treatments Pleural Source Type: news